Interleukin 1 beta and Tumor Necrosis Factor alpha (IL-1β and TNF-α)

Interleukin 1 beta (IL-1β) and Tumor Necrosis Factor alpha (TNF-α) are critical pro-inflammatory cytokines that mediate the body's innate immune response. IL-1β is produced as a pro-protein by activated macrophages and is cleaved into its active form by caspase-1 within the inflammasome complex (UniProt P01584). TNF-α is a pleiotropic cytokine primarily secreted by macrophages and T-cells, playing a central role in systemic inflammation and the acute phase response (UniProt P01375). Both cytokines are key drivers in the pathogenesis of chronic inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease, where they promote leukocyte recruitment and tissue destruction. Therapeutic targeting of these molecules with monoclonal antibodies (e.g., adalimumab for TNF-α, canakinumab for IL-1β) or receptor antagonists (e.g., anakinra) has become a cornerstone of treatment for autoimmune disorders. However, systemic inhibition of these pathways increases the risk of serious opportunistic infections, such as tuberculosis, necessitating careful screening and monitoring of patients (StatPearls, "TNF Inhibitors").

Other names

IL-1 betaTNF-alphaIL1BTNFACachectinCatabolinTumor necrosis factor ligand superfamily member 2Interleukin-1 family member 2

These targets are inhibited by biologic agents that either neutralize the cytokines directly or block their receptors, thereby preventing the activation of pro-inflammatory signaling pathways such as NF-κB and MAPK (StatPearls, "TNF Inhibitors"; StatPearls, "Interleukin-1 Inhibitors").